NZ595037A - Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides - Google Patents

Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides

Info

Publication number
NZ595037A
NZ595037A NZ595037A NZ59503710A NZ595037A NZ 595037 A NZ595037 A NZ 595037A NZ 595037 A NZ595037 A NZ 595037A NZ 59503710 A NZ59503710 A NZ 59503710A NZ 595037 A NZ595037 A NZ 595037A
Authority
NZ
New Zealand
Prior art keywords
cysteamine
inhibition
combination
biofilm
biofilm organisms
Prior art date
Application number
NZ595037A
Other languages
English (en)
Inventor
Neil Deborah O
Derry Mercer
Cedric Charrier
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of NZ595037A publication Critical patent/NZ595037A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595037A 2009-03-31 2010-03-31 Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides NZ595037A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16539609P 2009-03-31 2009-03-31
GBGB0905451.1A GB0905451D0 (en) 2009-03-31 2009-03-31 Biofilms
PCT/GB2010/000631 WO2010112848A2 (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms

Publications (1)

Publication Number Publication Date
NZ595037A true NZ595037A (en) 2013-07-26

Family

ID=40671951

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595037A NZ595037A (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides

Country Status (21)

Country Link
US (3) US9339525B2 (enExample)
EP (1) EP2413949B1 (enExample)
JP (1) JP5727994B2 (enExample)
KR (1) KR101852784B1 (enExample)
CN (2) CN104257645A (enExample)
AU (2) AU2010231136B2 (enExample)
BR (1) BRPI1012219C1 (enExample)
CA (1) CA2755878C (enExample)
CY (1) CY1121175T1 (enExample)
GB (1) GB0905451D0 (enExample)
IL (1) IL215369B2 (enExample)
MX (1) MX358018B (enExample)
NZ (1) NZ595037A (enExample)
PL (1) PL2413949T3 (enExample)
RU (1) RU2548786C2 (enExample)
SG (2) SG10201400926VA (enExample)
SI (1) SI2413949T1 (enExample)
TR (1) TR201821161T4 (enExample)
UA (1) UA106743C2 (enExample)
WO (1) WO2010112848A2 (enExample)
ZA (1) ZA201107140B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143889A1 (en) 2007-05-14 2008-11-27 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
TWI403330B (zh) * 2010-03-29 2013-08-01 Rise technology co ltd 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
GB201016733D0 (en) * 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
BR112012026880B1 (pt) * 2010-04-27 2021-03-16 Lysando Ag método para eliminação ou redução de um biofilme bacteriano, variante de endolisina ou variante de bacteriocina e seus usos
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
RU2013150536A (ru) 2011-05-12 2015-06-20 Смит & Невью Ортопедикс АГ Способ и топическая композиция для обработки ран, содержащая seaprose и его применение
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US20140315789A1 (en) * 2011-11-23 2014-10-23 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
ES2991989T3 (es) 2012-03-23 2024-12-05 Macro Biologics Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos
RU2014145270A (ru) * 2012-05-11 2016-07-10 Смит & Невью, Инк. Способ и композиция для разрушения бактериальной биопленки
WO2014016979A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物活性調節剤及び微生物の活性を調節する方法
US20160289287A1 (en) * 2013-08-27 2016-10-06 The University Of British Columbia Small cationic anti-biofilm and idr peptides
GB201405891D0 (en) * 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
US11103547B2 (en) 2016-02-04 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
EP3416669B1 (en) * 2016-02-19 2025-05-28 Klaus Brandenburg Means and methods for treating bacterial infections
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
EP3241570A1 (en) * 2016-05-02 2017-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide and hyaluronic acid coatings
JP7249149B2 (ja) * 2016-05-12 2023-03-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア バイオフィルムの堆積および産生を阻害するための組成物および方法
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
WO2018020435A1 (en) 2016-07-27 2018-02-01 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
EP3554491B1 (en) 2016-12-15 2023-02-15 Zambon S.p.A. N-acetylcysteine for use as antibacterial agent
WO2018112511A1 (en) * 2016-12-22 2018-06-28 Whiteley Corporation Pty Ltd Biofilm disrupting composition
EP3565613A4 (en) * 2017-01-05 2020-07-29 Cormedix Inc. ANTIMICROBIAL COMPOSITIONS, INCLUDING ANTIMICROBIAL HYDROGELS, EFFECTIVE AGAINST MATURE BIOFILMS
WO2018140707A1 (en) 2017-01-30 2018-08-02 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces
MX393548B (es) 2017-04-06 2025-03-24 Amicrobe Inc Composiciones y usos de polipéptidos catiónicos, sintéticos, antimicrobianos localmente aplicados con seguridad y desempeño mejorados.
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
CN108048359B (zh) * 2017-12-27 2020-12-01 广州立白企业集团有限公司 一种牙菌斑生物膜模型的培养方法和优化的生物膜活菌计数法及应用
EP3765057A4 (en) * 2018-03-13 2022-01-05 Peptilogics, Inc. TREATMENT OF IMPLANTS WITH SPECIFICALLY MODIFIED ANTIMICROBIAL AMPHIPHILE PEPTIDES
CN108753632A (zh) * 2018-05-25 2018-11-06 安徽中医药大学 一种溶解白念珠菌生物被膜胞外基质的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
FI3866775T3 (fi) * 2018-10-17 2025-07-10 Novabiotics Ltd Kysteamiini käytettäväksi keuhkosairauksien hoidossa
CN110402928A (zh) * 2019-08-08 2019-11-05 杭州博菲医疗器械有限公司 一种抑菌功能液及应用该抑菌功能液的导管组件
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
CN111675751B (zh) * 2020-04-08 2022-06-14 天津医科大学口腔医院 一种抗菌肽及其应用
GB202010268D0 (en) * 2020-07-03 2020-08-19 Novabiotics Ltd Nail formulations and treatment regimes
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
WO2000033895A1 (en) * 1998-12-07 2000-06-15 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
EP1778720B1 (en) * 2004-08-18 2010-09-01 Novabiotics Limited Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
US20070093894A1 (en) * 2005-10-25 2007-04-26 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
ZA200805191B (en) * 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
WO2009023356A2 (en) * 2007-05-25 2009-02-19 Omega-Biopharma (H.K.) Limited Materials and methods for treating influenza infections
CN102006785A (zh) * 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20160106689A1 (en) * 2014-09-22 2016-04-21 Novabiotics Limited Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds

Also Published As

Publication number Publication date
AU2010231136B2 (en) 2016-08-04
BRPI1012219A2 (pt) 2016-03-29
CA2755878C (en) 2018-04-24
SG10201400926VA (en) 2014-10-30
UA106743C2 (uk) 2014-10-10
MX358018B (es) 2018-08-02
US20190175528A1 (en) 2019-06-13
GB0905451D0 (en) 2009-05-13
IL215369A (en) 2013-02-03
ZA201107140B (en) 2012-06-27
AU2016210742A1 (en) 2016-08-25
PL2413949T3 (pl) 2019-04-30
AU2010231136A1 (en) 2011-09-29
TR201821161T4 (tr) 2019-01-21
BRPI1012219C1 (pt) 2021-05-25
CN102387794A (zh) 2012-03-21
US9339525B2 (en) 2016-05-17
SI2413949T1 (sl) 2019-02-28
IL215369B (en) 2022-10-01
US20120189682A1 (en) 2012-07-26
CN104257645A (zh) 2015-01-07
US20160206575A1 (en) 2016-07-21
JP2012522037A (ja) 2012-09-20
MX2011010258A (es) 2011-10-19
EP2413949A2 (en) 2012-02-08
IL215369B2 (en) 2023-02-01
RU2548786C2 (ru) 2015-04-20
SG174278A1 (en) 2011-10-28
WO2010112848A2 (en) 2010-10-07
JP5727994B2 (ja) 2015-06-03
AU2016210742B2 (en) 2017-08-10
CY1121175T1 (el) 2020-05-29
BRPI1012219B8 (pt) 2020-05-12
EP2413949B1 (en) 2018-10-10
KR20120003893A (ko) 2012-01-11
CA2755878A1 (en) 2010-10-07
KR101852784B1 (ko) 2018-04-30
WO2010112848A3 (en) 2011-01-27
CN102387794B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
NZ595037A (en) Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides
IL180727A0 (en) Antimicrobial peptides comprising an arginine and/or lysine -containing motif
WO2012002668A3 (en) Novel peptide and use thereof
CA2747703C (en) Compositions and methods for the treatment or the prevention of infections by e. coli
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
GB201016733D0 (en) Compounds and their use
WO2008076806A3 (en) Compositions and methods to potentiate colistin activity
EA021522B9 (ru) Противопаразитарные дигидроазоловые соединения и содержащие их композиции
UA105018C2 (uk) Акриламідопохідні, застосовні як інгібітори переходу мітохондріальної проникності
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
MX2011008043A (es) Derivados de actagardina.
WO2010034105A8 (en) Hepatitis c inhibitor compounds
NZ593524A (en) A nonapeptide with anti-tumour activity
NZ610732A (en) Novel angiotensin type 2 (at2) receptor agonists and uses thereof
ATE529430T1 (de) Caspase-hemmer-propharmaka
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
ITRM20040349A1 (it) Peptidi antibatterici e loro analoghi.
MY159790A (en) Highly bridged peptides from actinomadura namibiensis
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
WO2007125142A8 (es) Péptidos lineales antimicrobianos
MX2015008373A (es) Peptidos antimicrobianos, composiciones que los comprende y usos.
UA97633C2 (ru) Циклические антимикробные пептиды
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.
MD3124C2 (ro) Salicilidentiosemicarbazidaţi de cupru(II) care conţin sulfanilamide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 MAR 2017 BY RENEWALS TEAM

Effective date: 20140308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2018 BY RENEWALS TEAM

Effective date: 20170325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2019 BY RENEWALS TEAM

Effective date: 20180323

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2020 BY IP CENTRUM LIMITED

Effective date: 20190329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2021 BY IP CENTRUM LIMITED

Effective date: 20200330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2022 BY IP CENTRUM LIMITED

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2023 BY IP CENTRUM LIMITED

Effective date: 20220308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2024 BY IP CENTRUM LIMITED

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2025 BY IP CENTRUM LIMITED

Effective date: 20240306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2026 BY IP CENTRUM LIMITED

Effective date: 20250327